| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10261
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5252 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-93 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-235
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate |
2016-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2020-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-105582533-B |
| titleOfInvention |
Avian influenza virus and avian adenovirus bivalent inactivated vaccine |
| abstract |
The invention provides a combined inactivated vaccine of avian influenza virus and avian adenovirus, which is prepared from TCID of new strains of H9 subtype avian influenza virus QDY strain and I group 4 avian adenovirus YBAV-4 strain 50 /EID 50 High potency, good immunogenicity and can resist the attack of virus isolation in various places of H9 subtype and avian adenovirus diseases. The vaccine prepared by the invention has good safety, and does not have any local and systemic adverse reaction caused by the vaccine. The results of analysis of the data of the character test, the safety test and the efficacy test in the retention period test are compared with the results of single seedlings of the same type of products, and the double seedlings have no obvious difference and are stable and effective; the results of the efficacy tests prove that the bivalent and two single antibodies are kept at high level, and generate antibodies faster than the similar products, while the control group is negative. |
| priorityDate |
2016-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |